bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
CA153

Order Name (ชื่อการทดสอบ):
CA 15-3*

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 2:00 hours (120 mins)
 
Useful For (ประโยชน์การทดสอบ):
Determination of DF3 defined antigen in human serum.

Used as an aid in the management of Stage II and III breast cancer patients. Serial testing for patient CA 15-3
assay values should be used in conjunction with other clinical methods for monitoring breast cancer. 
 
Methodology (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName (ชื่อเรียกอื่นๆ) :
Cancer Antigen15-3
 
 
 
Test Code (รหัสการทดสอบ):
CA153

Order Name (ชื่อการทดสอบ):
CA 15-3*

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Serum, minimum volume 1 mL
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic vial
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Hemolysis: 4+ reject
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
Serum (keep in original tube) Refrigerated, 2oC to 8oC 8 hours
Serum Refrigerated, 2oC to 8oC 7 days
Frozen, -20oC 14 days
 
 
 
Test Code (รหัสการทดสอบ):
CA153

Order Name (ชื่อการทดสอบ):
CA 15-3*

 
Schedule (ตารางการทดสอบ):
Tested daily (24 hours)
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 2:00 hours (120 mins)
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time (ระยะเวลาเก็บสิ่งส่งตรวจ):
5 days
 
 
 
Test Code (รหัสการทดสอบ):
CA153

Order Name (ชื่อการทดสอบ):
CA 15-3*

 
 
Clinical Information (ข้อมูลทางคลินิก):
The ARCHITECT CA 15-3 assay values are defined by using the 115D8 and DF3 monoclonal antibodies. Monoclonal antibody 115D8, raised against human milk-fat globule membranes, and monoclonal antibody DF3, raised against a membrane enriched fraction of metastatic human breast carcinoma, react with epitopes expressed by a family of high molecular weight glycoproteins designated as polymorphic epithelial mucins (PEMs).

Research studies have indicated that CA 15-3 assay values are frequently elevated in patients with breast cancer. These studies have suggested that the CA 15-3 assay may be of clinical value for monitoring the response of patients undergoing therapy because increasing and decreasing values correlated with disease progression and regression, respectively. Additional published studies have suggested that increasing CA 15-3 assay values in patients at risk for breast cancer recurrence after primary therapy may be indicative of recurrent disease before it can be detected clinically. Elevations of CA 15-3 assay values have been reported in individuals with nonmalignant conditions such as cirrhosis, hepatitis, autoimmune disorders, and benign diseases of the ovary and breast. Non-mammary malignancies in which elevated CA 15-3 assay values have been reported include lung, colon, pancreatic, primary liver, ovarian, cervical, and endometrial. CA 15-3 assay values are not elevated in most normal individuals.

The CA 15-3 assay is not recommended as a screening procedure to detect cancer in the general population; however, use of the CA 15-3 assay as an aid in the management of breast cancer patients has been reported.
 
Reference Value (ค่าอ้างอิง):
0 - 31  U/mL
 
Clinical Reference (เอกสารอ้างอิง):
Manufacturer’s Reagent package insert Architect CA 15-3, November 2015, Abbott Laboratories, Diagnostic Division, Abbott Park IL 60064 USA.